NASDAQ · SCLX
Healthcare · Drug Manufacturers - General
$2.47
Down-$0.12 (-4.86%)
Updated Oct 24, 2026, 12:16 AM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SCLX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
SCLX closed at $2.47 after 20 trading sessions, down 49.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $2.56 | $2.60 | $2.449 | $2.47 | 33.42K |
| Oct 21, 2026 | $2.51 | $2.62 | $2.51 | $2.56 | 25.89K |
| Oct 20, 2026 | $2.55 | $2.68 | $2.52 | $2.53 | 35.74K |
| Oct 19, 2026 | $2.81 | $2.81 | $2.518 | $2.57 | 52.15K |
| Oct 16, 2026 | $2.82 | $2.8903 | $2.77 | $2.83 | 29.52K |
| Oct 15, 2026 | $2.83 | $2.85 | $2.77 | $2.82 | 12.54K |
| Oct 14, 2026 | $2.88 | $2.95 | $2.81 | $2.85 | 26.72K |
| Oct 13, 2026 | $2.81 | $3.225 | $2.79 | $2.88 | 33.97K |
| Oct 12, 2026 | $2.92 | $2.95 | $2.80 | $2.80 | 33.84K |
| Oct 9, 2026 | $2.96 | $3.1099 | $2.86 | $2.92 | 49.71K |
| Oct 8, 2026 | $3.49 | $3.5922 | $2.90 | $2.96 | 140.98K |
| Oct 7, 2026 | $3.90 | $3.90 | $3.445 | $3.49 | 82.15K |
| Oct 6, 2026 | $3.87 | $4.05 | $3.79 | $3.96 | 57.88K |
| Oct 5, 2026 | $4.13 | $4.49 | $3.81 | $3.82 | 59.62K |
| Oct 2, 2026 | $4.40 | $4.5888 | $4.00 | $4.06 | 108.44K |
| Oct 1, 2026 | $4.49 | $4.8786 | $4.40 | $4.41 | 16.09K |
| Sep 30, 2026 | $4.42 | $4.69 | $4.40 | $4.45 | 17.46K |
| Sep 29, 2026 | $4.48 | $4.535 | $4.3575 | $4.41 | 12.03K |
| Sep 28, 2026 | $4.89 | $4.90 | $4.45 | $4.49 | 73.22K |
| Sep 25, 2026 | $5.3658 | $5.3658 | $4.83 | $4.89 | 42.89K |
The latest Smart Investors Daily articles mentioning SCLX.
Company
Market Activity
Research & News
SCLX research
Company profile and research snapshot.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 11, 2025 | D. Boral Capital | Hold | — |
| Apr 2, 2025 | D. Boral Capital | Buy | — |
| Feb 28, 2025 | D. Boral Capital | Buy | — |
| Jan 27, 2025 | D. Boral Capital | Buy | — |
| Oct 21, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
The St. James Bank & Trust Company Ltd. ("St. James"), Omega & Corinth Group Ltd. and Marc Wade today announced that the U.S. District Court has granted their motion to compel arbitration and stay all
Yahoo · Jul 7, 2026
PALO ALTO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur” or the “Company”) (OTC: SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, today announced the signing of a binding term sheet with iHolding Group LLP (“iHolding”), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates that iHolding will purchase $100,000,000 o
Benzinga · Jul 7, 2026
Semnur Pharmaceuticals, Inc. ("Semnur" or the "Company") (OTC:SMNR) , a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain
Yahoo · Jul 6, 2026
Investing.com - U.S. stock index futures edged higher on Monday as investors returned from a long holiday weekend, with technology shares leading gains.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SCLX.
